Saturday 17 October 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 88.0%, free cash flow fell 16.6% and total debt fell 47.0%, each against the same quarter a year earlier.
0.15
0.04
−21.05%
Follow SLXN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (17,021.95%) | (897.46%) | 1,718.90% | (770.48%) |
+8 more TTM periods Free account |
|
| (277.96%) | (200.00%) | (236.40%) | (125.68%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
6,492.09% | (46,107.14%) | (305.12%) | (111.37%) | |
Free Cash Flow per Share |
(18.09) | (37.19) | (81.41) | (94.76) | |
Free Cash Flow |
(12.43) | (12.01) | (10.83) | (10.74) | |
Capital Expenditures |
— | — | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(539.97%) | (439.84%) | (106.27%) | (60.36%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
83.59 | (72.34) | (41.99) | (78.00) | |
Operating CF/Net income |
0.89 | 0.93 | 0.91 | 1.16 | |
Depreciation/Fixed assets |
0.60 | 0.52 | 0.56 | (0.04) | |
Capex/Depreciation |
0.00 | 0.00 | (0.64) | 7.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(18.09) | (37.19) | (81.35) | (94.70) | |
Capex per Share |
0.00 | 0.00 | (0.07) | (0.06) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates